TuHURA's Major Leap: FDA-Backed Phase 3 Trial Plus Strategic Acquisition Reshapes Cancer Pipeline FDA grants Special Protocol Assessment for Merkel cell carcinoma trial as TuHURA expands through VISTA inhibitor acquisition. $36M raised extends runway. Full analysis inside.

#HURA #KATN TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

www.stocktitan.net/news/HURA/tu-hura-biosci...